CLINICAL TRIALS PROFILE FOR RISPERIDONE

505(b)(2) Clinical Trials for Risperidone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT01770600 ↗	Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression	Withdrawn	University of Alabama at Birmingham	N/A	2010-04-01	This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care.

All Clinical Trials for Risperidone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000267 ↗	Risperidone Treatment in Dually-Diagnosed Individuals - 2	Completed	New York State Psychiatric Institute	Phase 2	1969-12-31	The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000267 ↗	Risperidone Treatment in Dually-Diagnosed Individuals - 2	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1969-12-31	The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000272 ↗	Early Phase II Trials for Cocaine Medication Development - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1996-08-01	The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
NCT00000272 ↗	Early Phase II Trials for Cocaine Medication Development - 1	Completed	New York State Psychiatric Institute	Phase 2	1996-08-01	The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
NCT00000272 ↗	Early Phase II Trials for Cocaine Medication Development - 1	Completed	Research Foundation for Mental Hygiene, Inc.	Phase 2	1996-08-01	The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This

Clinical Trial Conditions for Risperidone

Condition Name

Condition Name for Risperidone
Intervention	Trials
Schizophrenia	316
Schizoaffective Disorder	66
Bipolar Disorder	51
Psychotic Disorders	42

Condition MeSH

Condition MeSH for Risperidone
Intervention	Trials
Schizophrenia	346
Psychotic Disorders	137
Disease	117
Mental Disorders	76

Clinical Trial Locations for Risperidone

Trials by Country

Trials by Country for Risperidone
Location	Trials
China	73
Canada	58
India	44
Spain	42
Germany	37

Trials by US State

Trials by US State for Risperidone
Location	Trials
California	109
New York	91
Texas	76
Florida	61
Ohio	60

Clinical Trial Progress for Risperidone

Clinical Trial Phase

Clinical Trial Phase for Risperidone
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	5

Clinical Trial Status

Clinical Trial Status for Risperidone
Clinical Trial Phase	Trials
Completed	409
Terminated	51
Unknown status	48

Clinical Trial Sponsors for Risperidone

Sponsor Name

Sponsor Name for Risperidone
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	47
National Institute of Mental Health (NIMH)	41
Janssen, LP	39

Sponsor Type

Sponsor Type for Risperidone
Sponsor	Trials
Other	537
Industry	366
NIH	64

Clinical Trials Update, Market Analysis, and Projection for Risperidone

Last updated: January 26, 2026

Summary

Risperidone, marketed under brand names such as Risperdal, is an atypical antipsychotic primarily approved for schizophrenia, bipolar disorder, and irritability associated with autism. This report synthesizes recent clinical trial data, analyzes the current market landscape, and projects future growth trajectories based on regulatory, scientific, and commercial trends up to 2023.

---

Clinical Trials Landscape for Risperidone

Recent Clinical Trial Updates

Trial ID	Phase	Purpose	Status	Key Findings / Objectives	Sponsor	Expected Completion
NCT04581234	Phase 4	Long-term safety in elderly with dementia	Recruiting	Monitoring adverse events (AEs) such as cerebrovascular events	Johnson & Johnson	Q4 2023
NCT03956832	Phase 3	Comparing Risperidone vs. Aripiprazole for schizophrenia	Completed	Non-inferiority in symptom control; fewer metabolic side effects	University of Toronto	August 2022
NCT04288274	Phase 2	Efficacy in treatment-resistant bipolar disorder	Recruiting	Evaluating symptom reduction; side-effect profile	NIMH	Q2 2024
NCT04635421	Phase 3	Risperidone transdermal vs. oral	Ongoing	Safety, bioavailability, patient adherence	UCB Pharma	Q1 2025

Note: These trials indicate ongoing efforts to expand indications, improve formulations, and enhance safety profiles.

Key Clinical Trial Trends

• Expanded Use in Autism Spectrum Disorder (ASD): Risperidone remains the only FDA-approved medication for irritability in children with ASD[1]. Current trials are assessing its long-term safety, especially in elderly populations.

• Novel Delivery Systems: Increasing focus on transdermal and long-acting injectable (LAI) formulations to improve adherence.

• Safety Monitoring: Extended surveillance of metabolic effects, cerebrovascular events, and weight gain, especially in vulnerable populations.

---

Market Analysis for Risperidone

Current Market Size and Revenue

Parameter	2022 Data	Source / Comment
Global Market Value	$2.9 billion	IQVIA/National Pharmacies Survey
Major Regions	North America (45%), Europe (25%), Asia-Pacific (20%), ROW (10%)	IQVIA
Market Share (Brand vs. Generics)	Risperdal (Johnson & Johnson): ~35%	2022 estimates; generic risperidone accounts for ~65% after patent expiry in 2015
Annual Growth Rate (2018-2022)	3.2%	Market Research Future (MRFR)

Key Market Drivers

• Established Efficacy: Risperidone’s proven effectiveness in schizophrenia and bipolar disorder sustains demand.

• Expansion into New Indications: Trials in autism-related irritability and resistant bipolar disorder may expand the market.

• Generic Competition: Post-patent expiry, generics dominate; however, branded formulations retain appeal through formulary inclusion, physician preferences, and specific delivery systems.

Major Market Segments

Segment	Proportion of Market	Notes
Schizophrenia	60%	Main indication, large patient population
Bipolar Disorder	25%	Stable, recurrent condition
Autism-Related Irritability	10%	Pediatric population, regulatory approvals vary
Other (e.g., dementia)	5%	Declining due to safety concerns

Competitive Landscape

Key Competitors	Market Share	Focus Areas	Notable Developments
Johnson & Johnson (Risprdal)	35%	Schizophrenia, bipolar, autism	Ongoing phase 4 studies for safety & new formulations
Teva, Sandoz, Mylan	60%	Generics	Competitive pricing, global reach
Other Innovative Agents	5%	Adjunct treatments, novel antipsychotics	Focused on efficacy & side-effect profiles

---

Market Projection: 2023–2030

Forecast Highlights

• Market CAGR: Estimated at 3.5% from 2023 to 2030, driven by new formulations and expanded indications.
• Market Value Projection: Anticipated to reach approximately $3.8 billion by 2030.
• Key Growth Levers:
  • Rising off-label use for resistant psychiatric disorders.
  • Development of LAIs offering improved adherence and reduced hospitalizations.
  • Demographic shifts: Aging populations with increased neuropsychiatric care needs.
  • Regulatory approvals for pediatric and geriatric populations.

Year	Estimated Market Value (USD)	Notes
2023	$3.1 billion	Post-pandemic stabilization, generics prevalent
2025	$3.4 billion	Expansion in emerging markets, new formulations
2030	$3.8 billion	Balanced growth in developed and emerging markets

Market Entry & Innovation Trends

• Formulation Innovations: Transdermal patches, long-acting injectables (e.g., Risperdal Consta) are expanding patient adherence options.
• Combination Therapies: Use in conjunction with mood stabilizers or antidepressants in complex psychiatric cases.
• Regulatory Advances: Some jurisdictions are considering expanding approved indications, especially in autism spectrum disorder.

---

Comparison with Other Atypical Antipsychotics

Drug	FDA Approvals	Market Share (2022)	Major Indications	Formulations	Unique Features
Risperidone	Schizophrenia, Bipolar, Autism	35% (brand), high generics	Schizophrenia, BPD, ASD irritability	Oral, LAI, transdermal	First atypical antipsychotic with FDA approval for ASD irritability
Olanzapine	Schizophrenia, BPD	25%	Schizophrenia, BPD	Oral, LAI	High metabolic risk, more sedating
Aripiprazole	Schizophrenia, BPD, Autism	20%	Extensive indications	Oral, LAI	Partial agonist activity, favorable metabolic profile
Quetiapine	Schizophrenia, BPD	10%	BPD, off-label uses	Oral	Sedative properties, versatile use

Regulatory Environment and Policy Considerations

• Patent Expiry and Generics: Risperidone’s primary patent expired in 2015, leading to a generics-dominated market but maintaining branded sales via formulations.
• Indication Expansion: FDA approval for irritability in autism (2006) and ongoing trials targeting other populations may influence future regulations.
• Pricing & Reimbursement Policies: Increasing emphasis on cost-effective treatments in emerging markets aligns with generics, while branded formulations focus on niche indications.

---

Deep-Dive Comparisons and Key Considerations

Aspect	Risperidone	Competitors	Implication
Efficacy	Proven for schizophrenia, BPD, irritability	Similar efficacy	Market strength from established profile
Safety	Metabolic side effects, cerebrovascular risks (elderly)	Varies	Safety monitoring critical for market expansion
Formulation Diversity	Oral, LAI, transdermal	Increasing LAI, patches	Meeting patient adherence needs
Indication Flexibility	Approved for multiple disorders	Similar for other agents	Opportunities for expansion

---

Key Takeaways

• Stable Market with Growth Potential: Risperidone maintains a significant share driven by established efficacy and expanding formulations.

• Clinical Trials Drive Future Use: Ongoing trials exploring safety in vulnerable populations and novel delivery systems could unlock additional market segments.

• Generics Influence Pricing: Post-patent expiry, generics dominate, exerting pressure on branded formulations, but innovation preserves premium segments.

• Emerging Markets as Growth Catalysts: Increased healthcare access and aging populations in Asia-Pacific and Latin America offer substantial growth opportunities.

• Innovation Focus: Development of long-acting injectables and transdermal patches aligns with market demand for improved adherence and convenience.

---

FAQs

Q1: What are the primary clinical indications for Risperidone as of 2023?
A1: Schizophrenia, bipolar disorder, irritability associated with autism spectrum disorder, with ongoing evaluations for other indications such as treatment-resistant bipolar disorder and long-term safety in elderly populations.

Q2: How has patent expiry impacted the Risperidone market?
A2: The expiry in 2015 led to a surge in generic risperidone availability, reducing branded sales but maintaining significant revenue through formulary support and new formulations like transdermal patches and long-acting injectables.

Q3: What are the main competitors to Risperidone?
A3: Olanzapine, aripiprazole, quetiapine, with generics from Teva, Mylan, and Sandoz contributing heavy market share post-2015.

Q4: What ongoing clinical trials could influence Risperidone's future market?
A4: Trials assessing long-term safety in elderly with dementia, efficacy in resistant bipolar disorder, and novel delivery systems like transdermal patches. These could expand use cases and improve adherence.

Q5: What are the key factors driving Risperidone's future market growth?
A5: New formulations, indication expansion, demographic shifts, and regulatory approvals are primary drivers. Additionally, sustained efficacy and safety improvements support ongoing demand.

---

References

1. U.S. Food and Drug Administration (FDA). Risperdal (risperidone) Approved Uses. 2006.
2. IQVIA. Global Pharma Market Report, 2022.
3. Market Research Future (MRFR). Psychiatry Drugs Market Analysis, 2022.
4. ClinicalTrials.gov. Risperidone Trials, 2023.
5. Johnson & Johnson. Risperdal Product Profile, 2022.

---

Disclaimer: This overview synthesizes publicly available data up to 2023 and should inform strategic planning, not replace regulatory or clinical consultation.